A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

NCT ID: NCT05692154

Last Updated: 2025-09-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 95 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-23
• Study Completion Date: 2023-03-14

Brief Summary

This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms.

The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.

Detailed Description

The end of the study is defined as the date of the last visit of the last participant in the study.

A participant is considered to have completed the study if he/she has completed all visits of the study including Visit 5 (Day 5).

Conditions

Seasonal Allergic Rhinitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Arm A (active-active)

Two days of pre-treatment with Fexofenadine 180 mg each day in the morning on Day 2 and Day 3, then Fexofenadine180 mg after the pollen challenge on Day 4.

Group Type: EXPERIMENTAL

Fexofenadine

Intervention Type: DRUG

Fexofenadine oral tablet

Arm B (placebo-active)

Two days of pre-treatment with tablet of matching placebo each day in the morning on Day 2 and Day 3, then Fexofenadine180 mg after the pollen challenge on Day 4.

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

Fexofenadine matching placebo oral tablet

Interventions

Fexofenadine

Fexofenadine oral tablet

Intervention Type: DRUG

Placebo

Fexofenadine matching placebo oral tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participants are eligible to be included in the study only if all of the following criteria apply:
• Participant is willing to provide written informed consent.
• Adult participants (18 to 80 years old) suffering from seasonal allergic rhinitis (SAR) provoked by Ragweed pollen.
• Participants having a total nasal symptom score (TNSS)-3 ≥4 (with 3 nasal symptoms) at first pollen challenge at Visit 2.
• Having a 2-year history of SAR with Positive skin prick test to Ragweed allergen at screening (with a wheal diameter at least 3 mm larger than that produced by the negative control).

Exclusion Criteria

• History of anaphylaxis to Ragweed pollen History of asthma or exacerbations in the past 12 months requiring regular inhaled corticosteroids for greater than 4 weeks per year, any oral corticosteroid usage, any emergency department visit for asthma or any asthma-related hospitalization. Mild asthmatics treated only with pro re nata short-acting β2agonists, less than 2 doses per week can be enrolled.
• History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness.
• History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency, where, in the opinion of the study physician, participation in the trial would pose a risk or significant effect on the immune system.
• Presence or history of drug hypersensitivity to fexofenadine and/or its excipients.
• Participants unable to stop the following forbidden treatments/nutriments prior to pollen challenge:

• Antihistamines: within 3 days for first-generation antihistamines, within 2 days for second-generation antihistamines.
• Intranasal or inhaled corticosteroids: 7 days.
• Ocular, intranasal, or inhaled sodium cromoglycate: 14 days.
• High doses of systemic corticosteroids: 30 days.
• Leukotriene antagonists: 30 days.
• Intranasal or systemic decongestants: 3 days.
• Tricyclic antidepressants: 7 days.
• Any citrus fruits (grapefruit, orange, etc.) or their juices, as well as all fruit juices: 5 days.
• Aluminum-and-magnesium containing antacids: 7 days.
• Omalizumab/dupilumab: within 6 months
• Any contraindications to fexofenadine, according to the labeling.
• The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Opella Healthcare Group SAS, a Sanofi Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Investigational Site Number : 1240001

Kingston, Ontario, Canada

Countries

Canada

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://www.trialsummaries.com/Study/StudyDetails?id=25295&tenant=MT_SNY_9011

LPS17180 Plain Language Results Summary

Other Identifiers

U1111-1278-3949

Identifier Type: REGISTRY

Identifier Source: secondary_id

LPS17180

Identifier Type: -

Identifier Source: org_study_id